Frontier Medicines Corp. has unveiled FMC-242 as its newest development candidate. FMC-242 is a covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS proteins to inhibit downstream effector signaling in tumors without impacting normal functions and while minimizing the toxicities commonly associated with the broader class of inhibitors.